(SCLX) Scilex Holding - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US80880W1062
Stock: Patch, Migraine, Gout, Sciatica, Fibromyalgia
Total Rating 18
Risk 40
Buy Signal -1.63
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 125% |
| Relative Tail Risk | -12.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.28 |
| Alpha | -55.36 |
| Character TTM | |
|---|---|
| Beta | 1.018 |
| Beta Downside | 1.293 |
| Drawdowns 3y | |
|---|---|
| Max DD | 99.23% |
| CAGR/Max DD | -0.72 |
Description: SCLX Scilex Holding January 20, 2026
Scilex Holding Company (NASDAQ:SCLX) specializes in non-opioid pain-management therapies, commercializing three FDA-approved products: ZTlido (1.8 % lidocaine topical system) for post-herpetic neuralgia, ELYXYB oral solution for acute migraine, and GLOPERBA liquid colchicine for gout-flare prophylaxis.
The pipeline includes three late-stage candidates: SP-102 (SEMDEXA), a dexamethasone viscous gel for epidural injection that has finished a Phase 3 trial in sciatica; SP-103, a 5.4 % lidocaine topical system targeting chronic neck and low-back pain with Phase 2 data; and SP-104, a low-dose delayed-release naltrexone capsule for fibromyalgia that completed Phase 1. Development partnerships with Oishi/Itochu (lidocaine tapes) and Lifecore Biomedical (clinical-trial manufacturing) support these programs.
From a market perspective, the U.S. non-opioid chronic-pain segment is estimated at > $10 billion and growing at roughly 5 % CAGR, while Scilex’s Q2 2024 revenue of $8.2 million reflects a 27 % YoY increase, giving the firm a cash runway of about 14 months at current burn rates.
For a deeper dive into SCLX’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-rich overview.
Piotroski VR‑10 (Strict, 0-10) 3.0
| Net Income: -375.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA -2.02 > 1.0 |
| NWC/Revenue: -848.5% < 20% (prev -438.2%; Δ -410.3% < -1%) |
| CFO/TA 0.09 > 3% & CFO 23.8m > Net Income -375.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (11.6m) vs 12m ago 208.3% < -2% |
| Gross Margin: 68.59% > 18% (prev 0.68%; Δ 6791 % > 0.5%) |
| Asset Turnover: 21.45% > 50% (prev 54.92%; Δ -33.47% > 0%) |
| Interest Coverage Ratio: -39.55 > 6 (EBITDA TTM -322.1m / Interest Expense TTM 8.25m) |
Altman Z'' -15.00
| A: -1.24 (Total Current Assets 16.5m - Total Current Liabilities 358.9m) / Total Assets 275.9m |
| B: -3.22 (Retained Earnings -888.7m / Total Assets 275.9m) |
| C: -1.73 (EBIT TTM -326.1m / Avg Total Assets 188.2m) |
| D: -1.94 (Book Value of Equity -885.3m / Total Liabilities 455.6m) |
| Altman-Z'' Score: -32.33 = D |
Beneish M -4.00
| DSRI: 0.52 (Receivables 11.9m/31.6m, Revenue 40.4m/55.2m) |
| GMI: 0.99 (GM 68.59% / 68.17%) |
| AQI: 1.63 (AQ_t 0.93 / AQ_t-1 0.57) |
| SGI: 0.73 (Revenue 40.4m / 55.2m) |
| TATA: -1.45 (NI -375.8m - CFO 23.8m) / TA 275.9m) |
| Beneish M-Score: -4.74 (Cap -4..+1) = AAA |
What is the price of SCLX shares?
As of February 07, 2026, the stock is trading at USD 8.49 with a total of 62,393 shares traded.
Over the past week, the price has changed by -0.35%, over one month by -35.19%, over three months by -49.90% and over the past year by -33.72%.
Over the past week, the price has changed by -0.35%, over one month by -35.19%, over three months by -49.90% and over the past year by -33.72%.
Is SCLX a buy, sell or hold?
Scilex Holding has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy SCLX.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the SCLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 490 | 5671.5% |
| Analysts Target Price | 490 | 5671.5% |
| ValueRay Target Price | 3.6 | -57.4% |
SCLX Fundamental Data Overview February 04, 2026
P/E Forward = 2.7397
P/S = 1.5927
P/B = 28.8516
Revenue TTM = 40.4m USD
EBIT TTM = -326.1m USD
EBITDA TTM = -322.1m USD
Long Term Debt = 845.0k USD (from longTermDebt, last fiscal year)
Short Term Debt = 55.3m USD (from shortTermDebt, last quarter)
Debt = 67.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 66.8m USD (from netDebt column, last quarter)
Enterprise Value = 131.1m USD (64.3m + Debt 67.7m - CCE 878.0k)
Interest Coverage Ratio = -39.55 (Ebit TTM -326.1m / Interest Expense TTM 8.25m)
EV/FCF = 5.50x (Enterprise Value 131.1m / FCF TTM 23.8m)
FCF Yield = 18.17% (FCF TTM 23.8m / Enterprise Value 131.1m)
FCF Margin = 59.02% (FCF TTM 23.8m / Revenue TTM 40.4m)
Net Margin = -931.2% (Net Income TTM -375.8m / Revenue TTM 40.4m)
Gross Margin = 68.59% ((Revenue TTM 40.4m - Cost of Revenue TTM 12.7m) / Revenue TTM)
Gross Margin QoQ = 68.48% (prev 66.94%)
Tobins Q-Ratio = 0.48 (Enterprise Value 131.1m / Total Assets 275.9m)
Interest Expense / Debt = 4.14% (Interest Expense 2.80m / Debt 67.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -257.7m (EBIT -326.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.05 (Total Current Assets 16.5m / Total Current Liabilities 358.9m)
Debt / Equity = -0.38 (negative equity) (Debt 67.7m / totalStockholderEquity, last quarter -176.9m)
Debt / EBITDA = -0.21 (negative EBITDA) (Net Debt 66.8m / EBITDA -322.1m)
Debt / FCF = 2.80 (Net Debt 66.8m / FCF TTM 23.8m)
Total Stockholder Equity = -207.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -199.7% (out of range, set to none)
RoE = 181.1% (negative equity) (Net Income TTM -375.8m / Total Stockholder Equity -207.5m)
RoCE = 157.8% (negative capital employed) (EBIT -326.1m / Capital Employed (Equity -207.5m + L.T.Debt 845.0k))
RoIC = 155.0% (negative operating profit) (NOPAT -257.7m / Invested Capital -166.2m)
WACC = 6.39% (E(64.3m)/V(131.9m) * Re(9.67%) + D(67.7m)/V(131.9m) * Rd(4.14%) * (1-Tc(0.21)))
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 73.42%
[DCF Debug] Terminal Value 78.94% ; FCFF base≈18.6m ; Y1≈12.7m ; Y5≈6.30m
Fair Price DCF = 15.06 (EV 172.7m - Net Debt 66.8m = Equity 105.9m / Shares 7.03m; r=6.39% [WACC]; 5y FCF grow -36.96% → 2.90% )
[DCF Warning] FCF declining rapidly (-36.96%), DCF may be unreliable
EPS Correlation: -76.60 | EPS CAGR: -81.00% | SUE: -4.0 | # QB: 0
Revenue Correlation: 17.17 | Revenue CAGR: 6.76% | SUE: -1.36 | # QB: 0
EPS next Year (2026-12-31): EPS=3.11 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+109.6% | Growth Revenue=+749.7%
P/S = 1.5927
P/B = 28.8516
Revenue TTM = 40.4m USD
EBIT TTM = -326.1m USD
EBITDA TTM = -322.1m USD
Long Term Debt = 845.0k USD (from longTermDebt, last fiscal year)
Short Term Debt = 55.3m USD (from shortTermDebt, last quarter)
Debt = 67.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 66.8m USD (from netDebt column, last quarter)
Enterprise Value = 131.1m USD (64.3m + Debt 67.7m - CCE 878.0k)
Interest Coverage Ratio = -39.55 (Ebit TTM -326.1m / Interest Expense TTM 8.25m)
EV/FCF = 5.50x (Enterprise Value 131.1m / FCF TTM 23.8m)
FCF Yield = 18.17% (FCF TTM 23.8m / Enterprise Value 131.1m)
FCF Margin = 59.02% (FCF TTM 23.8m / Revenue TTM 40.4m)
Net Margin = -931.2% (Net Income TTM -375.8m / Revenue TTM 40.4m)
Gross Margin = 68.59% ((Revenue TTM 40.4m - Cost of Revenue TTM 12.7m) / Revenue TTM)
Gross Margin QoQ = 68.48% (prev 66.94%)
Tobins Q-Ratio = 0.48 (Enterprise Value 131.1m / Total Assets 275.9m)
Interest Expense / Debt = 4.14% (Interest Expense 2.80m / Debt 67.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -257.7m (EBIT -326.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.05 (Total Current Assets 16.5m / Total Current Liabilities 358.9m)
Debt / Equity = -0.38 (negative equity) (Debt 67.7m / totalStockholderEquity, last quarter -176.9m)
Debt / EBITDA = -0.21 (negative EBITDA) (Net Debt 66.8m / EBITDA -322.1m)
Debt / FCF = 2.80 (Net Debt 66.8m / FCF TTM 23.8m)
Total Stockholder Equity = -207.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -199.7% (out of range, set to none)
RoE = 181.1% (negative equity) (Net Income TTM -375.8m / Total Stockholder Equity -207.5m)
RoCE = 157.8% (negative capital employed) (EBIT -326.1m / Capital Employed (Equity -207.5m + L.T.Debt 845.0k))
RoIC = 155.0% (negative operating profit) (NOPAT -257.7m / Invested Capital -166.2m)
WACC = 6.39% (E(64.3m)/V(131.9m) * Re(9.67%) + D(67.7m)/V(131.9m) * Rd(4.14%) * (1-Tc(0.21)))
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 73.42%
[DCF Debug] Terminal Value 78.94% ; FCFF base≈18.6m ; Y1≈12.7m ; Y5≈6.30m
Fair Price DCF = 15.06 (EV 172.7m - Net Debt 66.8m = Equity 105.9m / Shares 7.03m; r=6.39% [WACC]; 5y FCF grow -36.96% → 2.90% )
[DCF Warning] FCF declining rapidly (-36.96%), DCF may be unreliable
EPS Correlation: -76.60 | EPS CAGR: -81.00% | SUE: -4.0 | # QB: 0
Revenue Correlation: 17.17 | Revenue CAGR: 6.76% | SUE: -1.36 | # QB: 0
EPS next Year (2026-12-31): EPS=3.11 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+109.6% | Growth Revenue=+749.7%